Biologics/Immunotherapy News

Clinicians do not have to wait for cutting-edge research to improve treatment. Breakthroughs already can impact care, Jessica Warren Grayson, MD, MS, member of Healio’s Allergy/Asthma Peer Perspective Board, said.

Mepolizumab reduced the need for maintenance oral corticosteroids and systemic corticosteroid bursts among patients with severe asthma, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Children and adolescents with allergic asthma and serum IgE levels that exceed approved dosing ranges still benefitted from omalizumab, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Patients with asthma treated with biologics did not have higher rates of SARS-CoV-2 infection than the general population, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Children aged 1 to 11 years with eosinophilic esophagitis safely achieved histologic disease remission after 16 weeks of treatment with the fully human monoclonal antibody dupilumab, according to the results of a phase 3 trial.

Children and adults exhibited the same likelihood of reaching desensitization via peanut oral immunotherapy, with similar rates of adverse events, according to study findings.

The biologics mepolizumab, dupilumab and benralizumab showed minimal differences in efficacy and safety in treating eosinophilic asthma, according to a review of eight studies published in The Journal of Allergy and Clinical Immunology.

Lanadelumab prevented hereditary angioedema attacks among patients aged 2 to younger than 12 years with no serious adverse events, according to a study presented at European Academy of Allergy and Clinical Immunology Hybrid Congress.

Dupilumab appeared effective and well-tolerated among children and adolescents with moderate to severe atopic dermatitis, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Patients who began taking or who switched biologics for severe asthma consistently experienced meaningfully reduced exacerbations, according to a real-world analysis published in Annals of Allergy, Asthma & Immunology.